Thank you to all that attended the Friends Annual Meeting 2022! Please find links below to watch each keynote and panel discussion, as well as the panel white papers.
Friends of Cancer Research Annual Meeting 2022
Thursday, November 17, 202210:00AM EST – 3:00PM ESTWashington Marriott Georgetown1221 22nd St NW, Washington, DC
Click HERE to watch the full meeting.
Friends of Cancer Research (Friends) is proud to host our 15th Annual Meeting to address critical issues in the development of new oncology drugs. After our last two Annual Meetings were hosted virtually, we are excited to be able to welcome attendees back in-person in a safe environment. Each Friends Annual Meeting brings together leaders from federal health and regulatory agencies, academic research, the private sector, and patient advocates to propose unique approaches toward current challenges in drug development.
Annual Meeting 2022 Agenda
10:00 AM: Welcome
- Jeff Allen, President & CEO, Friends of Cancer Research
10:05 AM: Morning Keynote Conversation
- Robert Califf, Commissioner, U.S. FDA
- Richard Pazdur, Director, Oncology Center of Excellence, U.S. FDA
10:40 AM: Panel 1 — Applying Learnings from COVID-19 to Advance Clinical Trial Conduct
Project overview and key findings–Joseph Unger, Fred Hutchinson Cancer Center
- Nathan Pennell, Cleveland Clinic (Moderator)
- Rita Livadas, BD
- Peggy McCann, Merck & Co., Inc.
- Therica Miller, Ichahn School of Medicine at Mount Sinai
- Timil Patel, U.S. FDA
- Gary Smith, National Cancer Institute
- Joseph Unger, Fred Hutchinson Cancer Center
11:40 AM: Break
11:55 AM: Panel 2 — Incorporating Patient Reported Outcomes to Inform Dose Selection and Optimization
Introductory remarks–Paul Kluetz, U.S. FDA
- Peter Trask, Genentech (Moderator)
- Vishal Bhatnagar, U.S. FDA
- Serban Ghiorghiu, AstraZeneca
- Kristin McJunkins, Patient Advocate
- Devin Peipert, Northwestern University
12:55 PM: Lunch and Networking
1:25 PM: Lunch Keynote Conversation
- Monica Bertagnolli, Director, National Cancer Institute
- Ellen Sigal, Chair & Founder, Friends of Cancer Research
1:50 PM: Break
1:55 PM: Panel 3 — Accelerating Investigation of New Therapies in Earlier Metastatic Treatment Settings: Discussions about FDA OCE’s Project FrontRunner
- Panel White Paper
- Colleen Mockbee, OncXerna Therapeutics (Moderator)
- Lola Fashoyin-Aje, U.S. FDA, OCE
- Keith Flaherty, MGH Cancer Center, Harvard Medical School
- David Hyman, Loxo@Lilly
- Anne Quinn Young, Multiple Myeloma Research Foundation
- Craig Tendler, Janssen
2:55 PM: Closing Remarks
3:00 PM: Meeting Adjournment
